{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:23:25Z","timestamp":1791487405942,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11606-025-09350-8","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T14:07:21Z","timestamp":1739282841000},"page":"43-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Early Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in U.S. South"],"prefix":"10.1007","volume":"41","author":[{"given":"Dylan","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren F.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria D.","family":"Cantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5999-6655","authenticated-orcid":false,"given":"Meredith","family":"Lora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"7","key":"9350_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385(7):595-608. https:\/\/doi.org\/10.1056\/NEJMoa2101016.","journal-title":"N Engl J Med."},{"issue":"10337","key":"9350_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-89. https:\/\/doi.org\/10.1016\/S0140-6736(22)00538-4.","journal-title":"Lancet."},{"issue":"8","key":"9350_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2023.9865","volume":"330","author":"R Chou","year":"2023","unstructured":"Chou R, Spencer H, Bougatsos C, Blazina I, Ahmed A, Selph S. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023;330(8):746-63. https:\/\/doi.org\/10.1001\/jama.2023.9865.","journal-title":"JAMA."},{"issue":"6","key":"9350_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s11904-020-00533-y","volume":"17","author":"SK Calabrese","year":"2020","unstructured":"Calabrese SK. Understanding, Contextualizing, and Addressing PrEP Stigma to Enhance PrEP Implementation. Curr HIV\/AIDS Rep. 2020;17(6):579-88. https:\/\/doi.org\/10.1007\/s11904-020-00533-y.","journal-title":"Curr HIV\/AIDS Rep."},{"issue":"6","key":"9350_CR5","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/cid\/ciy297","volume":"67","author":"DP Serota","year":"2018","unstructured":"Serota DP, Rosenberg ES, Lockard AM, Rolle CM, Luisi N, Cutro S, et al. Beyond the Biomedical: Preexposure Prophylaxis Failures in a Cohort of Young Black Men Who Have Sex With Men in Atlanta, Georgia. Clin Infect Dis. 2018;67(6):965-70. https:\/\/doi.org\/10.1093\/cid\/ciy297.","journal-title":"Clin Infect Dis."},{"key":"9350_CR6","unstructured":"Prevention CfDCa. HV Surveillance Supplemental Report: Estimated HIV Incidence and Prevalence in the United States, 2018\u20132022 2024. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/156513.\u00a0Accessed\u00a023 Dec 2024."},{"issue":"10","key":"9350_CR7","doi-asserted-by":"publisher","first-page":"e23173","DOI":"10.2196\/23173","volume":"22","author":"PS Sullivan","year":"2020","unstructured":"Sullivan PS, Woodyatt C, Koski C, Pembleton E, McGuinness P, Taussig J, et al. A Data Visualization and Dissemination Resource to Support HIV Prevention and Care at the Local Level: Analysis and Uses of the AIDSVu Public Data Resource. J Med Internet Res. 2020;22(10):e23173. https:\/\/doi.org\/10.2196\/23173.","journal-title":"J Med Internet Res."},{"issue":"Suppl 2","key":"9350_CR8","doi-asserted-by":"publisher","first-page":"e26109","DOI":"10.1002\/jia2.26109","volume":"26","author":"SE Stansfield","year":"2023","unstructured":"Stansfield SE, Heitner J, Mitchell KM, Doyle CM, Milwid RM, Moore M, et al. Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis. J Int AIDS Soc. 2023;26 Suppl 2(Suppl 2):e26109. https:\/\/doi.org\/10.1002\/jia2.26109.","journal-title":"J Int AIDS Soc."},{"issue":"1","key":"9350_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/infdis\/jiaa552","volume":"223","author":"KM Maloney","year":"2021","unstructured":"Maloney KM, Le Guillou A, Driggers RA, Sarkar S, Anderson EJ, Malik AA, Jenness SM. Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model. J Infect Dis. 2021;223(1):72-82. https:\/\/doi.org\/10.1093\/infdis\/jiaa552.","journal-title":"J Infect Dis."},{"issue":"2","key":"9350_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/qai.0000000000003029","volume":"91","author":"R Balasubramanian","year":"2022","unstructured":"Balasubramanian R, Kasaie P, Schnure M, Dowdy DW, Shah M, Fojo AT. Projected Impact of Expanded Long-Acting Injectable PrEP Use Among Men Who Have Sex With Men on Local HIV Epidemics. J Acquir Immune Defic Syndr. 2022;91(2):144-50. https:\/\/doi.org\/10.1097\/qai.0000000000003029.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"10","key":"9350_CR11","doi-asserted-by":"publisher","first-page":"e0309811","DOI":"10.1371\/journal.pone.0309811","volume":"19","author":"EE Tolley","year":"2024","unstructured":"Tolley EE, Bula A, Chitukuta M, Ndimande-Khoza N, Etima J, Namey E, et al. Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084. PLoS ONE. 2024;19(10):e0309811. https:\/\/doi.org\/10.1371\/journal.pone.0309811.","journal-title":"PLoS ONE."},{"issue":"4","key":"9350_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/qai.0000000000001945","volume":"80","author":"AM Minnis","year":"2019","unstructured":"Minnis AM, Browne EN, Boeri M, Agot K, van der Straten A, Ahmed K, et al. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019;80(4):394-403. https:\/\/doi.org\/10.1097\/qai.0000000000001945.","journal-title":"J Acquir Immune Defic Syndr."},{"key":"9350_CR13","unstructured":"Scott H, Hanscom B, Hutchinson C, Lucas J, Gaur A, Kelley C, et al. Cabotegravir for HIV PrEP in U.S. Black Men and Transgender Women Who Have Sex With Men. Conference on Retroviruses and Opportunistic Infections; Seattle, Washington 2023."},{"issue":"1","key":"9350_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/coh.0000000000000894","volume":"20","author":"CA Koss","year":"2025","unstructured":"Koss CA, Parikh UM. Long-acting preexposure prophylaxis: early data on roll-out in the United States. Curr Opin HIV AIDS. 2025;20(1):25-31. https:\/\/doi.org\/10.1097\/coh.0000000000000894.","journal-title":"Curr Opin HIV AIDS."},{"issue":"18","key":"9350_CR15","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2024.21493","volume":"332","author":"LM Mann","year":"2024","unstructured":"Mann LM, Zhu W, Huang YA, Kourtis AP, Fanfair RN, Hoover KW. Trends in Oral and Injectable HIV Preexposure Prophylaxis Prescriptions in the US, 2013-2023. Jama. 2024;332(18):1580-3. https:\/\/doi.org\/10.1001\/jama.2024.21493.","journal-title":"Jama."},{"key":"9350_CR16","unstructured":"Inc VH. Apretude Package Insert. Research Triange Park, NC2021."},{"issue":"2","key":"9350_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/cid\/ciad537","volume":"78","author":"I Sharma","year":"2024","unstructured":"Sharma I, Hill A. Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis. Clin Infect Dis. 2024;78(2):386-94. https:\/\/doi.org\/10.1093\/cid\/ciad537.","journal-title":"Clin Infect Dis."},{"key":"9350_CR18","unstructured":"Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 Update: a clinical practice guideline. 2021. p. 1\u2013108."},{"issue":"3","key":"9350_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/cid\/ciz894","volume":"71","author":"DP Serota","year":"2020","unstructured":"Serota DP, Rosenberg ES, Sullivan PS, Thorne AL, Rolle CM, Del Rio C, et al. Pre-exposure Prophylaxis Uptake and Discontinuation Among Young Black Men Who Have Sex With Men in Atlanta, Georgia: A Prospective Cohort Study. Clin Infect Dis. 2020;71(3):574-82. https:\/\/doi.org\/10.1093\/cid\/ciz894.","journal-title":"Clin Infect Dis."},{"issue":"12","key":"9350_CR20","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1007\/s10461-020-02901-6","volume":"24","author":"PW Colson","year":"2020","unstructured":"Colson PW, Franks J, Wu Y, Winterhalter FS, Knox J, Ortega H, et al. Adherence to Pre-exposure Prophylaxis in Black Men Who Have Sex with Men and Transgender Women in a Community Setting in Harlem, NY. AIDS Behav. 2020;24(12):3436-55. https:\/\/doi.org\/10.1007\/s10461-020-02901-6.","journal-title":"AIDS Behav."},{"issue":"9","key":"9350_CR21","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1080\/09540121.2023.2217375","volume":"35","author":"JD Sharpe","year":"2023","unstructured":"Sharpe JD, Siegler AJ, Sanchez TH, Guest JL, Sullivan PS. Effects of mode of transportation on PrEP persistence among urban men who have sex with men. AIDS Care. 2023;35(9):1411-9. https:\/\/doi.org\/10.1080\/09540121.2023.2217375.","journal-title":"AIDS Care."},{"issue":"4","key":"9350_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1521\/aeap.2023.35.4.309","volume":"35","author":"AP Barnett","year":"2023","unstructured":"Barnett AP, Arnold T, Elwy AR, Brock JB, Giorlando KK, Sims-Gomillia C, et al. Considerations for PrEP Implementation at Federally Qualified Health Centers in Mississippi: Perspectives From Staff and Patients. AIDS Educ Prev. 2023;35(4):309-19. https:\/\/doi.org\/10.1521\/aeap.2023.35.4.309.","journal-title":"AIDS Educ Prev."},{"key":"9350_CR23","unstructured":"McCain J. The Importance of a Thorough Benefits Investigation to Help Navigate Medical vs Pharmacy Benefit: National Association of Medication Access & Patient Advocacy; 2022 [12\/23\/2024]. Available from: https:\/\/www.namapa.org\/medical-vs-pharmacy-benefit.\u00a0Accessed\u00a023 Dec 2024."},{"key":"9350_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae531","author":"MA Spinelli","year":"2024","unstructured":"Spinelli MA, Bisom-Rapp E, Heise MJ, Camp C, Appa A, Liu AY, et al. High Retention and Adherence With Rapid Long-acting Injectable Preexposure Prophylaxis Implementation in an Urban Safety Net Clinic Population. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae531.","journal-title":"Clin Infect Dis."},{"key":"9350_CR25","unstructured":"Hazra A, Schneider J, Murray M, Williams J, Halbur D, Creticos C. Insurance Type Drives Cabotegravir Delays: Real-World Long-Acting PrEP Outcomes in the Midwest US. Conference on Retroviruses and Opportunistic Infections; Denver, Colorado 2024."},{"key":"9350_CR26","unstructured":"Turner C, Wagner G, Pfeil A, Willcott A, LonerganT, Hill L, Blumenthal J. Implementing Long-Acting Cabotegravir for HIV Preexposure Prophylaxis in a Large Urban HIV Clinic. Conference on Retroviruses and Opportunistic Infections; Denver, Colorado 2024."},{"key":"9350_CR27","doi-asserted-by":"publisher","unstructured":"Collins LF, Corbin-Johnson D, Asrat M, Morton ZP, Dance K, Condra A, et al. Early Experience Implementing Long-Acting Injectable Cabotegravir\/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South. Open Forum Infect Dis. 2022;9(9). https:\/\/doi.org\/10.1093\/ofid\/ofac455.","DOI":"10.1093\/ofid\/ofac455"},{"key":"9350_CR28","doi-asserted-by":"publisher","unstructured":"Johnson K, Sawkin MT. Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine. Drugs Context. 2022;11. https:\/\/doi.org\/10.7573\/dic.2021-9-2.","DOI":"10.7573\/dic.2021-9-2"},{"issue":"Supplement_4","key":"9350_CR29","doi-asserted-by":"publisher","first-page":"S541","DOI":"10.1093\/cid\/ciac716","volume":"75","author":"SE Cooper","year":"2022","unstructured":"Cooper SE, Rosenblatt J, Gulick RM. Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries. Clin Infect Dis. 2022;75(Supplement_4):S541-S8. https:\/\/doi.org\/10.1093\/cid\/ciac716.","journal-title":"Clin Infect Dis."},{"issue":"2","key":"9350_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/apc.2023.0248","volume":"38","author":"T McCrimmon","year":"2024","unstructured":"McCrimmon T, Collins LF, Perez-Brumer A, Bazzi AR, Shaffer VA, Kerrigan D, et al. Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States. AIDS Patient Care STDS. 2024;38(2):61-9. https:\/\/doi.org\/10.1089\/apc.2023.0248.","journal-title":"AIDS Patient Care STDS."},{"issue":"1","key":"9350_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s43058-024-00631-7","volume":"5","author":"AM Agovi","year":"2024","unstructured":"Agovi AM, Thompson CT, Craten KJ, Fasanmi E, Pan M, Ojha RP, Thompson EL. Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system. Implement Sci Commun. 2024;5(1):93. https:\/\/doi.org\/10.1186\/s43058-024-00631-7.","journal-title":"Implement Sci Commun."},{"issue":"1","key":"9350_CR32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/coh.0000000000000899","volume":"20","author":"RR Patel","year":"2025","unstructured":"Patel RR, Mayer KH. Why is roll-out of long-acting PrEP agents so slow? Curr Opin HIV AIDS. 2025;20(1):48-53. https:\/\/doi.org\/10.1097\/coh.0000000000000899.","journal-title":"Curr Opin HIV AIDS."},{"key":"9350_CR33","doi-asserted-by":"publisher","unstructured":"Altamirano JA, Shukla P, Barnett SK. 1531. Early Real-World Experience of Long-Acting Cabotegravir (CAB) for HIV Pre-Exposure Prophylaxis (PrEP) in a Large Community-Based Clinic Network (CAN Community Health): Utilization and PrEP Persistence. Open Forum Infect Dis. 2023;10(Supplement_2). https:\/\/doi.org\/10.1093\/ofid\/ofad500.1366.","DOI":"10.1093\/ofid\/ofad500.1366"},{"key":"9350_CR34","doi-asserted-by":"crossref","unstructured":"Harris N, DeSilva K, Kuriakose R, Sorlie S, Reed S, Oliver N, Moanna A, Webster A, Cartwright E. Implementation and Uptake of Long-Acting Injectable PrEP at Atlanta VA Healthcare System. Infectious Diseases Week; Los Angeles, California 2024.","DOI":"10.1093\/ofid\/ofae631.715"},{"issue":"12","key":"9350_CR35","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1080\/09540121.2024.2397128","volume":"36","author":"J Gonzalez","year":"2024","unstructured":"Gonzalez J, Rebolledo PA, Siegler AJ, Huang W, Mayer KH, Cantos VD. Development of a home-based pre-exposure prophylaxis care delivery system for long-acting injectable cabotegravir: a formative exploration of patient preferences. AIDS Care. 2024;36(12):1882-90. https:\/\/doi.org\/10.1080\/09540121.2024.2397128.","journal-title":"AIDS Care."},{"key":"9350_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae472","author":"SE Kirk","year":"2024","unstructured":"Kirk SE, Young C, Berry H, Hanson R, Moreland A, Fonner V, et al. Comparison of At-Home Versus In-Clinic Receipt of Long-Acting Injectable Cabotegravir\/Rilpivirine. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae472.","journal-title":"Clin Infect Dis."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09350-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09350-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09350-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:08:59Z","timestamp":1770772139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-09350-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["9350"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-09350-8","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"Dr. Dylan Baker has received research grant funds from Viiv Healthcare and has received compensation from Viiv Healthcare for participation on a medication advisory board, paid to Emory University. Dr. Valeria Cantos has received research grant funds from Gilead Sciences, paid to Emory University. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}